A Welcome Revival of Vaccine Research
This article was originally published in SRA
Every once in a while, public health needs intersect with new technology and there is an advance in human health. This may be happening in the area of vaccines where there has been visible progress in developing new platform technologies for producing and delivering vaccines. This applies to both prophylactic vaccines, which are designed to prevent disease by producing an immune response, and therapeutic vaccines, which treat existing diseases. The threat of a flu pandemic is partially driving this innovation. But big manufacturers are also beginning to see new markets open up to treat adolescents and the elderly in addition to the traditional paediatric population.
You may also be interested in...
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.